Nathan, Paul; Zweifel, Martin; Padhani, Anwar R; Koh, Dow-Mu; Ng, Matthew; Collins, David J; Harris, Adrian; Carden, Craig; Smythe, Jon; Fisher, Nita; Taylor, N Jane; Stirling, J James; Lu, Shiao-Ping; Leach, Martin O; Rustin, Gordon J S; Judson, Ian (2012). Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Clinical cancer research, 18(12), pp. 3428-39. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-11-3376
Full text not available from this repository. (Request a copy)The vascular disrupting agent (VDA) combretastatin A4 phosphate (CA4P) induces significant tumor necrosis as a single agent. Preclinical models have shown that the addition of an anti-VEGF antibody to a VDA attenuates the revascularization of the surviving tumor rim and thus significantly increases antitumor activity.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology |
UniBE Contributor: |
Zweifel, Martin |
ISSN: |
1078-0432 |
Publisher: |
American Association for Cancer Research |
Language: |
English |
Submitter: |
Factscience Import |
Date Deposited: |
04 Oct 2013 14:36 |
Last Modified: |
05 Dec 2022 14:11 |
Publisher DOI: |
10.1158/1078-0432.CCR-11-3376 |
PubMed ID: |
22645052 |
Web of Science ID: |
000307502100023 |
URI: |
https://boris.unibe.ch/id/eprint/14285 (FactScience: 221161) |
Actions (login required)
 |
Edit item |